The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-12. Anything still debated is marked as such rather than presented as settled.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The distinction between Jack and the player has also informed debate over ludonarrative dissonance, a term introduced by game designer Clint Hocking in a 2007 critique of BioShock. Hocking argued that the game permits players to pursue self-interest through its mechanics while obliging Jack to help Atlas through its narrative, creating a conflict between the values expressed through play and those expressed through the story. In a 2026 reassessment, Connor Jackson disputed this reading. Jackson argued that Jack's conditioning provides an in-universe explanation for his obedience to Atlas and cautioned against assuming that the motivations of a controllable avatar must correspond to those of the player. He also emphasized that the rescue-or-harvest decisions concerning the Little Sisters have substantial narrative consequences, and therefore considered BioShock's treatment of agency more complex than a simple contradiction between an inflexible story and flexible gameplay. Jennings identified this disagreement as characteristic of the wider scholarship on BioShock. Although many studies have treated the game as evidence that video-game agency is fundamentally illusory, others have distinguished between different kinds and degrees of agency rather than treating control as either wholly present or absent. She argued that even choices constrained by a designed system can produce meaningful experiences of responsibility, investment, and interpretation, and used the extensive debate surrounding BioShock to argue for a more contingent understanding of agency in games.
== Awards == 2009 – Bayer Innovators Award; awarded by Bayer New Zealand. 2011 – Supreme Award, Endoform by Mesynthes; awarded by Wellington Gold Awards. 2014 – Fastest Growing Manufacturer; awarded by Deloitte Fast 50. 2015 – New Zealand's Bioscience Company of the Year; awarded by NZBio. 2022 – Most Innovative Dressing or Device, Gold Award; awarded by Journal of Wound Care.
Each double-stranded DNA has a 'critical temperature' (Tc) lower than its Tm. The PCR amplification efficiency drops measurably below the Tc. The Tc is dependent on DNA sequence. Two template DNA fragments differing by only one or two nucleotide mismatches will have different amplification efficiencies if the denaturation step of PCR is set to the Tc. Keeping these principles in mind the authors developed the following general protocol:
Sources: en.wikipedia.org
Laboratory robotics is the act of using robots in biology, chemistry or engineering labs. For example, pharmaceutical companies employ robots to move biological or chemical samples around to synthesize novel chemical entities or to test pharmaceutical value of existing chemical matter. Advanced laboratory robotics can be used to completely automate the process of science, as in the Robot Scientist project. Laboratory processes are suited for robotic automation as the processes are composed of repetitive movements (e.g., pick/place, liquid/solid additions, heating/cooling, mixing, shaking, and testing). Many laboratory robots are commonly referred as autosamplers, as their main task is to provide continuous samples for analytical devices.
== Overdose == Acute overdosage is often manifested by emesis, lethargy, ataxia, tachycardia and seizures. Plasma, serum or blood concentrations of sertraline and norsertraline, its major active metabolite, may be measured to confirm a diagnosis of poisoning in hospitalized patients or to aid in the medicolegal investigation of fatalities. As with most other SSRIs its toxicity in overdose is considered relatively low.
In October 2023, Hamas launched a surprise attack on Israel that devolved into an intensified conflict, jeopardizing the administration's push to normalize relations between Israel and Saudi Arabia. Biden stated his unequivocal support for Israel and condemned the attack by Hamas, but discouraged Israel from initiating a ground invasion of Gaza. Upon Israel's retaliation against Hamas, Biden deployed aircraft carriers in the region to deter others from joining the war, and called for an additional $14 billion in military aid to Israel. He later began pressuring Israel to address the growing humanitarian crisis in the Gaza Strip. Biden rejected calls for a ceasefire but said he supported "humanitarian pauses" to deliver aid to the Gaza Strip. He asked Israel to pause its invasion of Gaza for at least three days to allow for hostage negotiations; Israel agreed to daily four-hour pauses. He also directed the U.S. military to facilitate the delivery of humanitarian aid to Palestinians in Gaza. Biden has said he is a Zionist. He has faced criticism for his unwavering support for Israel. Officials have urged him to take a harder stance against Israel, criticizing his administration's leniency and support despite the Israeli government's contentious offensive, which has led to significant civilian casualties and humanitarian crises. Following the killing of Palestinian civilians receiving food aid on February 29, 2024, Biden said the current level of aid flowing into Gaza was insufficient. On March 3, the U.S. military began airdropping food aid into Gaza.
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. A randomised controlled trial compared maintenance therapy with gradual dose reduction or discontinuation among people with long-term psychosis. At 2 years, people in the reduction group were twice as likely to relapse (25%) as those in the maintenance group (13%). Moreover, those in the reduction group had no improvement in social functioning (a measure combining people's ability to look after themselves, work, study and take part in family and social activities), side effects, quality of life, symptoms, or bodyweight. There is evidence that withdrawal syndrome of antipsychotics can result in psychosis. This has occurred in patients who had previously no history of psychosis, but were taking antipsychotics for another reason. Tardive dyskinesia can also occur when the medication is stopped. Unexpected psychotic episodes have been observed in patients withdrawing from clozapine. This is referred to as supersensitivity psychosis, not to be equated with tardive dyskinesia. Tardive dyskinesia may abate during withdrawal from the antipsychotic agent, or it may persist.
Sources: en.wikipedia.org
=== Motion preservation and facet arthroplasty === Independent reviews place TOPS within a broader group of posterior motion-preserving technologies developed to address the trade-off between decompression, stability, and retained segmental motion. Unlike lumbar disc replacement, which principally addresses disc pathology, facet arthroplasty is intended to restore stability after decompression in patients whose disease involves the posterior spinal elements, including the facet joints. Reviews identify preservation of motion and the potential to reduce adjacent-segment disease as key proposed advantages, while emphasizing the importance of patient selection and the need for continued long-term data on implant durability, revision, and adjacent-segment outcomes.
During translation, ribosomes convert a sequence of mRNA (messenger RNA) to an amino acid sequence. Each 3-base-pair-long segment of mRNA is a codon which corresponds to one amino acid or stop signal. Amino acids can have multiple codons that correspond to them. Ribosomes do not directly attach amino acids to mRNA codons. They must utilize tRNAs (transfer RNAs) as well. Transfer RNAs can bind to amino acids and contain an anticodon which can hydrogen bind to an mRNA codon. The process of bind an amino acid to a tRNA is known as tRNA charging. Here, the enzyme aminoacyl-tRNA-synthetase catalyzes two reactions. In the first one, it attaches an AMP molecule (cleaved from ATP) to the amino acid. The second reaction cleaves the aminoacyl-AMP producing the energy to join the amino acid to the tRNA molecule. Ribosomes have two subunits, one large and one small. These subunits surround the mRNA strand. The larger subunit contains three binding sites: A (aminoacyl), P (peptidyl), and E (exit). After translational initiation (which is different in prokaryotes and eukaryotes), the ribosome enters the elongation period which follows a repetitive cycle. First a tRNA with the correct amino acid enters the A site. The ribosome transfers the peptide from the tRNA in the P site to the new amino acid on the tRNA in the A site. The tRNA from the P site will be shifted into the E site where it will be ejected. This continually occurs until the ribosome reaches a stop codon or receives a signal to stop.
===== Alcohol ===== Repeated alcohol exposure alters both DNA methylation and hydroxymethylation of the OPRK1 promoter in the nucleus accumbens, a key reward centre in alcohol-preferring rodent models. Chronic intermittent ethanol exposure reduces both 5-methylcytosine and 5-hydroxymethylcytosine percentages in the OPRK1 promoter, leading to changes in receptor expression correlated with addiction-related motivational and reward behaviours.
== History == Avalglucosidase alfa's safety data was obtained from four clinical trials (trial 1/NCT02782741, trial 2/NCT01898364, trial 3/NCT02032524, trial 4/NCT03019406). These trials enrolled 124 participants with late-onset Pompe disease and 22 participants with infantile-onset Pompe disease. The participants were from 22 countries around the world, including the United States. Avalglucosidase alfa was evaluated in four trials of 146 participants with Pompe disease. Trial 1 evaluated the benefits and side effects of avalglucosidase alfa, and all four trials evaluated the side effects of avalglucosidase alfa. In trial 1, participants received either avalglucosidase alfa or another drug (called the active comparator) intravenously once every two weeks for 49 weeks. Neither the participants nor the healthcare providers knew which treatment was being given until after week 49. Participants in this trial were followed for up to five years. The benefit of avalglucosidase alfa was evaluated by comparing the change in lung function and distance walked between participants who received avalglucosidase alfa to the change in participants who were treated with the active comparator.
Transgender health care includes the prevention, diagnosis and treatment of physical and mental health conditions which affect transgender individuals. A major component of transgender health care is gender-affirming care, the medical aspect of gender transition. Questions implicated in transgender health care include gender variance, sex reassignment therapy, health risks (in relation to violence and mental health), and access to healthcare for trans people in different countries around the world. Gender-affirming health care can include psychological, medical, physical, and social behavioral care. The purpose of gender-affirming care is to help a transgender individual conform to their desired gender identity. In the 1920s, physician Magnus Hirschfeld conducted formal studies to understand gender dysphoria and human sexuality and advocated for communities that were marginalized. His research and work provided a new perspective on gender identity, gender expression, and sexuality. This was the first time there was a challenge against societal norms. In addition to his research, Hirschfeld also coined the term transvestite, which in modern terms is known as "transgender". Hirschfeld's work was ended during the Nazi German era when many transgender individuals were arrested and sent to concentration camps.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.